Welcome to BREATHER Plus

Can young people living with HIV safely take weekends off dolutegravir-based HIV treatment?
BREATHER Plus is a randomised open-label two-arm, 96-week trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily dolutegravir/tenofovir-based triple ART in virologically suppressed HIV-infected adolescents aged 12 to 19 years of age in sub-Saharan Africa.